May 21 - 22, 2014 | Westin Boston Waterfront | Boston, MA

Fourteenth Annual

Structure-Based Drug Design
Using Structure ...
Current Drug
Target Breakdown

Miscellaneous 2%
DNA 1%
Integrins 1%
Other Receptors 4%

Enzymes 47%

Nuclear Hormone
Recep...
Upcoming SlideShare
Loading in …5
×

Structure-Based Drug Design Facts & Figures Infographic

338 views
173 views

Published on

Among 32 pharma and biotech companies surveyed, structure-based drug design is the most prevalent activity with the most players emphasizing the fragment-based variation.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
338
On SlideShare
0
From Embeds
0
Number of Embeds
8
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Structure-Based Drug Design Facts & Figures Infographic

  1. 1. May 21 - 22, 2014 | Westin Boston Waterfront | Boston, MA Fourteenth Annual Structure-Based Drug Design Using Structure and Rational Design to Accelerate Discovery WHAT’S NEW THIS YEAR: • Coverage of novel targets and compounds including macrocycles, epigenetic targets, and BACE inhibitors • Case studies and experimental follow up - see how Constellation, Heptares, AstraZeneca, and others are leading the SBDD charge • Expanded sessions on GPCR design and drug discovery • Showcase of different approaches for working with the similar targets CAMBRIDGE HEALTHTECH INSTITUTE 250 First Avenue | Suite 300 Needham, MA 02494 PRSRT STD US POSTAGE PAID PERMIT NO. 6 HUDSON, MA Fourteenth Annual Structure-Based Drug Design Using Structure and Rational Design to Accelerate Discovery Hear case studies from: • Arena Pharmaceuticals • Astex • AstraZeneca • Bristol-Myers Squibb • Carmolex • Carmot Therapeutics • Constellation Pharmaceuticals • Genentech • Heptares Therapeutics UK • Merck • Novartis • Structural Genomics Consortium • Takeda • Vernalis, Ltd. Drug Discovery FACTS & FIGURES FACT: Among 32 pharma and biotech companies surveyed, structure-based drug design is the most prevalent activity with the most players emphasizing the fragment-based variation.
  2. 2. Current Drug Target Breakdown Miscellaneous 2% DNA 1% Integrins 1% Other Receptors 4% Enzymes 47% Nuclear Hormone Receptors and Transporters 8% Ion Channels 7% GPCRs 30% FACT: CONSIDER THIS cost of bringing a FACT: The average market is $1.3 billion new drug to FACT: Fewer than 1 in 10 medicines that start being tested in human clinical trials will succeed In 2012 the FDA approved 39 new drugs FACT: The pharmaceutical market will reach nearly $ 1,200,000,000,000 USD by 2016 How will CHI’s 14th Annual Structure-Based Drug Design conference help to advance the drug discovery field? By addressing topics that matter: 25% GPCRs By bringing together industry leaders: Attendee Profile Executive 11% Title Director 12% Manager 8% Professor 12% Scientist/Technologist 46% Sales & Marketing 6% 50% New techniques and strategies Other 5% Computational Chemistry 15% Function Medicinal Chemistry 17% Drug Discovery 13% 45% Novel targets and compounds Discovery Technologies 6% Structural Biology 9% Structural Chemistry 13% Biochemistry 11% Keynote Speaker Chas Bountra, Ph.D., Professor, Translational Medicine, Department of Clinical Medicine; Associate Head, Medical Sciences; Chief Scientist, Structural Genomics Consortium, University of Oxford Molecular Modeling 5% Other 11% Academic 24% Biotech 41% Government/ Research Institutions Register and View Full Details: healthtech.com/structure-based-drug-design Register by February 28 and Save up to $400! Mention keycode “INW” when registering 3% Pharmaceutical 32% USA 60% Europe 25% Asia 10% ROW Sources: Forbes, Insight Pharma Reports: Medicinal Chemistry, FDA.gov Company Type 5% Region

×